Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 14, 2010, detailing the outcomes of its Annual Meeting of Shareholders held on June 11, 2010. The primary focus of the filing is the shareholder votes on director elections and the ratification of the independent auditor. Investors can take comfort in the strong shareholder support for the company's leadership and its chosen accounting firm, indicating stability and confidence in governance and financial oversight. The report confirms the election of three Class I Directors to three-year terms, with all nominees receiving overwhelming support. Additionally, the appointment of PricewaterhouseCoopers, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2010, was overwhelmingly ratified. This strong endorsement from shareholders on key governance matters suggests a positive sentiment towards Regeneron's management and its financial reporting processes.
Key Highlights
- 1Regeneron held its Annual Meeting of Shareholders on June 11, 2010.
- 2All nominated Class I Directors were elected for three-year terms expiring in 2013.
- 3Leonard S. Schleifer, Eric M. Shooter, and George D. Yancopoulos were re-elected as directors.
- 4Shareholder support for director nominees was robust, with substantial 'Votes For' and minimal 'Votes Withheld'.
- 5The appointment of PricewaterhouseCoopers, LLP as the independent auditor for fiscal year 2010 was ratified.
- 6The ratification of the auditor received overwhelming approval, with a significant majority of 'Votes For'.